Area of research
Genetics · Hematology
Research interest
Research interests include Coagulation, Bradykinin, Polyphosphates, and Angioedema, Hemophilia Treatment and Research, Immunodeficiency and Autoimmune Disorders, and Autoimmune Bullous Skin Diseases.
Hereditary Angioedema with Normal C1 Inhibitor: an Updated International Consensus Paper on Diagnosis, Pathophysiology, and Treatment
Diagnostic testing for chronic spontaneous urticaria with or without angioedema: The do's, don't and maybe's
Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension
Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic Review
The Chronic Angioedema Registry (CARE): Rationale, Methods and Implementation
An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update
The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema
Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series
Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report
Consensus on treatment goals in hereditary angioedema: A global Delphi initiative
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
Impact of lanadelumab on health‐related quality of life in patients with hereditary angioedema in the HELP study
Definition, aims, and implementation of GA<sup>2</sup>LEN/HAEi Angioedema Centers of Reference and Excellence
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
The International/Canadian Hereditary Angioedema Guideline
Hereditary angioedema: an update on causes, manifestations and treatment
Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks
International Consensus on the Use of Genetics in the Management of Hereditary Angioedema
Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update
Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks
Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry
Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema
Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema
The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update
Understanding the evolving phenotype of vascular complications in telomere biology disorders
Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The <scp>OPuS</scp>‐2 study
Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor